“An Unusual Skin Adverse Event After Switching from Intravenous to Subcutaneous VEDOLIZUMAB Therapy in Patients With Ulcerative Colitis”. 2023. Archives of Clinical and Medical Case Reports 7 (1): 77-79. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22706.